Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Microbot Medical ( (MBOT) ) has provided an update.
On June 9, 2025, Microbot Medical announced the expansion of its commercial team with the addition of Michael Lytle as head of Sales Operations & Analytics, in preparation for the anticipated U.S. launch of the LIBERTY System in the third quarter of 2025. The company is actively engaged with the FDA, with a 510(k) decision expected in the same quarter, and this timeline is not expected to impact the planned launch, indicating confidence in their strategic growth and market readiness.
The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers to advanced robotic systems.
Average Trading Volume: 2,468,032
Technical Sentiment Signal: Buy
Current Market Cap: $102.2M
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue